Accepted for Publication: July 31, 2012.
Author Contributions: Drs Giacchero, Ramacciotti, Schlumberger, and Robert had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Robert. Acquisition of data: Giacchero, Ramacciotti, Arnault, Brassard, Maksimovic, Mateus, Tomasic, Wechsler, Schlumberger, and Robert. Analysis and interpretation of data: Baudin, Wechsler, and Robert. Drafting of the manuscript: Giacchero, Ramacciotti, Maksimovic, Wechsler, Schlumberger, and Robert. Critical revision of the manuscript for important intellectual content: Arnault, Brassard, Baudin, Mateus, Tomasic, Wechsler, and Robert. Statistical analysis: Robert. Administrative, technical, and material support: Ramacciotti and Baudin. Study supervision: Robert.
Conflict of Interest Disclosures: Drs Schlumberger and Robert serve as consultants to AstraZeneca, a manufacturer of vandetanib, and Dr Schlumberger has received research funds from AstraZeneca. Dr Schlumberger also serves as a consultant to Amgen Eisai and Exelixis and has received research funds from Amgen and Exelixis. Dr Robert is consultant for Bristol-Myers Squibb, Roche, GlaxoSmithKline, and Novartis.
Additional Contributions: We are indebted to Lorna Saint Ange for editing.